T. Rowe Price Associates
IRON icon

T. Rowe Price Associates’s Disc Medicine IRON Stock Holding History

T. Rowe Price Associates’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
1,875,399
+326,049
+21% +$22.4M 0.01% 608
2026
Q1 		$99.1M Sell
1,549,350
-148,655
-9% -$10.3M 0.01% 614
2025
Q4 		$135M Buy
1,698,005
+371,576
+28% +$31.4M 0.01% 568
2025
Q3 		$87.7M Sell
1,326,429
-189,196
-12% -$11.3M 0.01% 650
2025
Q2 		$80.3M Buy
1,515,625
+157,371
+12% +$7.39M 0.01% 617
2025
Q1 		$67.4M Sell
1,358,254
-36,383
-3% -$2.02M 0.01% 634
2024
Q4 		$88.4M Buy
1,394,637
+262,690
+23% +$15.2M 0.01% 593
2024
Q3 		$55.6M Buy
1,131,947
+9,753
+0.9% +$458K 0.01% 728
2024
Q2 		$50.6M Buy
1,122,194
+177,981
+19% +$6.05M 0.01% 721
2024
Q1 		$58.8M Buy
944,213
+353,382
+60% +$22.9M 0.01% 686
2023
Q4 		$34.1M Buy
590,831
+63,092
+12% +$3.23M ﹤0.01% 807
2023
Q3 		$24.8M Buy
527,739
+325,069
+160% +$16.3M ﹤0.01% 871
2023
Q2 		$9M Buy
+202,670
New +$7.19M ﹤0.01% 1093
2021
Q2 		– Sell
-25,000
Closed -$9.65M – 2939
2021
Q1 		$9.65M Buy
+25,000
New +$11.2M ﹤0.01% 1400

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

T. Rowe Price Associates's IRON Position: Q2 2026 in Review

T. Rowe Price Associates increased its Disc Medicine (IRON) stake by 21% in Q2 2026, buying an estimated $22.4M and bringing the position to 1,875,399 shares worth $137M. The position accounts for 0.01% of the portfolio, ranked #608.

T. Rowe Price Associates first reported a position in IRON in Q1 2021 and has held it in 14 quarters since. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • T. Rowe Price Associates held 1,875,399 shares of Disc Medicine worth $137M as of Q2 2026.
  • T. Rowe Price Associates bought 326,049 Disc Medicine shares in Q2 2026, an estimated $22.4M.
  • Disc Medicine made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #608 holding.
  • T. Rowe Price Associates first reported a position in Disc Medicine in Q1 2021 and has held it in 14 quarters since.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.